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There are currently three oral medications approved for the treatment of multiple sclerosis
(MS). Two of these medications, Fingolimod, and Teriflunomide, are considered to be
anti-inflammatory agents, while dimethyl fumarate (DMF) is thought to trigger a robust
antioxidant response, protecting vulnerable cells during an MS attack. We previously
proposed that epsilon toxin from the gut bacterium, Clostridium perfringens, may initiate
newly forming MS lesions due to its tropism for blood-brain barrier (BBB) vasculature
and central nervous systemmyelin. Because gut microbiota will be exposed to these oral
therapies prior to systemic absorption, we sought to determine if these compounds affect
C. perfringens growth in vitro. Here we show that Fingolimod, Teriflunomide, and DMF
indeed inhibit C. perfringens growth. Furthermore, several compounds similar to DMF in
chemical structure, namely α, β unsaturated carbonyls, also known asMichael acceptors,
inhibit C. perfringens. Sphingosine, a Fingolimod homolog with known antibacterial
properties, proved to be a potent C. perfringens inhibitor with a Minimal Inhibitory
Concentration similar to that of Fingolimod. These findings suggest that currently
approved oral MS therapies and structurally related compounds possess antibacterial
properties that may alter the gut microbiota. Moreover, inhibition of C. perfringens growth
and resulting blockade of epsilon toxin production may contribute to the clinical efficacy
of these disease-modifying drugs.
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INTRODUCTION
Multiple sclerosis (MS) is the most common non-traumatic neurological disease of young adults
in Western Europe and North America (Conway and Cohen, 2010). Although traditionally
considered an autoimmune disease that specifically targets central nervous system myelin
(Frohman et al., 2006), increasingly, investigators have been pursuing the idea that host-pathogen
interactions may play a role in the MS disease process (Collins et al., 2012). Indeed, investigations
into how the gut microbiota may trigger or modulate MS relapses are currently under way. With
the advent of the first oral treatments for MS, Fingolimod, Teriflunomide, and dimethyl fumarate
(DMF), a reasonable question arises. Do these oral medications possess antibacterial properties,
and if so, could modulation of gut bacteria contribute to protection against MS relapse?
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We have previously proposed that a bacterial neurotoxin,
epsilon toxin, from the anaerobic gut bacterium, Clostridium
perfringens, may play a pivotal role in triggering newly forming
MS lesions (Rumah et al., 2013, 2015; Linden et al., 2015). Epsilon
toxin (ETX) is a rational candidate MS trigger due to its tropism
for the blood-brain barrier (BBB) and for the myelin sheath;
both of which are specifically damaged during each MS relapse
(Dorca-Arévalo et al., 2008; Rumah et al., 2013; Linden et al.,
2015). Remarkably, newly formingMS lesions display evidence of
BBB breakdown, oligodendrocyte cell death and early microglial
activation in the absence of a peripheral inflammatory infiltrate
(Barnett and Prineas, 2004). While the triggering agent of
these early pathologic changes remains unknown, C. perfringens
epsilon toxin serves as a provocative candidate due to its tissue
specificity and resultant mechanistic plausibility (Rumah et al.,
2013, 2015; Linden et al., 2015).
C. perfringens is an anaerobic, spore forming, gram-positive
bacillus that is sub-classified into five distinct toxinotypes based
on differential exotoxin production (Table 1). C. perfringens
type A typically colonizes the human gut with a prevalence of
63% among healthy individuals (Carman et al., 2008), while
C. perfringens types B and D, the producers of ETX, are
commonly found in the intestines of ruminant animals such as
sheep, goats, and cattle but not humans (Popoff, 2011). ETX toxin
is a potent neurotoxin secreted as a 33 kDa inactive precursor
during the logarithmic growth phase of C. perfringens in the
mammalian intestine. This poorly active precursor is cleaved
by gut trypsin, chymotrypsin and/or an additional clostridial
exotoxin, lamda toxin. The 28.6 kDa enzymatic cleavage product
permeablizes the gut epithelium, enters the blood stream and
binds to receptors on the luminal surface of brain endothelial
cells. Once bound to brain microvessels, ETX oligomerizes
and forms a heptameric pore in the endothelial cell plasma
membrane. Brain endothelial cell damage leads to breakdown
of the BBB (Popoff, 2011). In addition to its known effects on
BBB vasculature, ETX has been found to specifically bind to and
damage myelin when incubated with mammalian brain slices
(Dorca-Arévalo et al., 2008; Linden et al., 2015; Wioland et al.,
2015). This unique ability to interact specifically with the tissues
that are damaged in MS, the BBB, and CNS myelin, makes it a
promising candidate as an environmental MS trigger.
Fingolimod was the first oral therapy to be approved for
the treatment of MS. It was rationally engineered from the
antifungal molecule Myriocin, which was later shown to possess
immunosuppressive properties. Fingolimod and Myriocin are
both structurally homologous to sphingosine, a lipid that is a
necessary component of cell membrane sphingolipids (Strader
et al., 2011). Similar to Myriocin, sphingosine is also known
to possess antimicrobial properties. However, while Myriocin
is antifungal in nature, sphingosine is antibacterial (Fischer
et al., 2012). Interestingly, Fingolimod has been shown to mimic
sphingosine’s antibacterial properties by protecting the cystic
fibrosis transmembrane conductance regulator (CFTR) knockout
mouse from luminal airway infection by Pseudomonas auerginosa
(Pewzner-Jung et al., 2014).
In the context of MS, Fingolimod is phosphorylated in
the bloodstream and subsequently binds to the lymphocyte
TABLE 1 | Clostridium perfringens toxinotypes, genotypes, and
associated diseases.
A α Humans: Gangrene, toxic enteritis, food poisoning, sporadic
diarrhea, some cases of SIDS.
Fowl: Necrotic enteritis.
Foals, pigs: Diarrhea.
B α, β, ε Newborn Lambs: Dysentery.
Newborn Calves and Foals: Hemorrhagic enteritis.
Sheep and Goats: Enterotoxemia. Focal symmetric
encephalomalacia.
C α, β Humans: Necrotic enteritis (Pigbel).
Piglets, Lambs, Calves and Foals: Necrotic enteritis.
Sheep: Enterotoxemia.
D α, ε Lambs, Sheep, Calves and Goats: Enterotoxemia. Focal symmetric
encephalomalacia.
E α, ι Calves: Enterotoxemia.
sphingosine-1-phosphate receptor 1 (S1PR1), causing rapid
internalization of S1PR1. In the absence of surface S1PR1,
lymphocytes are unable to egress from lymphoid tissues and
cannot traffic to target tissues such as the brain; thus the rationale
that Fingolimod may reduce the risk of MS relapse and the
severity of attacks through immune modulation (Strader et al.,
2011).
Teriflunomide is the active metabolite of the
immunosuppressant Lenflunomide, which is currently approved
for the treatment of rheumatoid arthritis (Munier-Lehmann
et al., 2013). Teriflunomide inhibits de novo pyrimidine synthesis
in rapidly dividing cells such as clonally expanding lymphocytes,
potentially mitigating an autoimmune attack against myelin.
More specifically, Teriflunomide non-competitively inhibits
dihydroorotate dehydrogenase, an enzyme involved in the first
step of de novo pyrimidine synthesis. Memory B cells and T cells
remain unaffected by Teriflunomide as they divide more slowly
and can synthesize DNA by utilizing the pyrimidine salvage
pathway (Bar-Or et al., 2014). Interestingly, dihydroorotate
dehydrogenase inhibitors have been shown to arrest the growth
of unicellular organisms such as plasmodium falciparum
presumably by inhibiting de novo pyrimidine synthesis (Pavadai
et al., 2016).
DMF is a fumaric acid ester, which was originally investigated
for use as an antimicrobial preservative1. It was first used
therapeutically to treat psoriasis based on a hypothesis that
psoriasis is caused by a defect in fumarate mediated carbohydrate
metabolism in the skin. In the early 2000s, a German neurologist
noticed that MS patients taking DMF for concurrent psoriasis
showed stabilization of their MS symptoms and a reduction in
relapse rates (Phillips and Fox, 2013).
DMF has been shown to react with thiol-containing molecules
such as the cellular antioxidant, glutathione, and the cysteine
residues of proteins via a chemical reaction called the Michael
1Pest control. Patent Publication Number: US2218181 A.
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addition (Brennan et al., 2015). Although DMF initially depletes
mammalian cells of glutathione, its proposed protective action
in MS stems from its ability to alkylate key cysteine residues in
the redox sensitive protein Kelch-Like ECH-Associated Protein
1 (Keap1). Keap1 normally inhibits Nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) from translocating to the nucleus
and activating antioxidant gene expression. When the cysteine
residues of Keap1 are oxidized by reactive oxygen species (ROS)
or organic electrophiles such as DMF, Keap1 dissociates from
Nrf-2, allowing nuclear translocation to occur. This elicits a
robust antioxidant cellular response. The initial decrease in
cellular glutathione after DMF treatment is followed by a sharp
glutathione increase via the Nrf-2 pathway, which may protect
vulnerable cells in MS (Phillips and Fox, 2013).
Although Fingolimod, Teriflunomide, and DMF have
proposed mechanisms for how they protect the central nervous
system from MS mediated damage, one unexplored possibility
is that these orally administered agents may inhibit the growth
of neurotoxin-secreting gut bacteria. Because, during log-phase
growth, C. perfringens secretes ETX, a toxin that specifically
targets the BBB and the myelin sheath, we chose to investigate
the effect of these oral MS therapies on C. perfringens growth in
vitro.
METHODS
Drugs and Compounds
All drugs and compounds used in this study were purchased from
Sigma Aldrich.
Bacterial Strains and Growth Conditions
C. perfringensATCC 13124 (type A), ATCC 3626 (type B), ATCC
51880 (type C), ATCC 3631 (type D), ATCC 27324 (type E), and
two type A clinical isolates provided by New York Presbyterian
Hospital were used for the initial screen while the “type strain,”
ATCC 13124, was used for all subsequent experiments. Bacteria
were cultured anaerobically at 37◦C overnight using the GasPak
100 system (BD). Anaerobiosis was achieved by pre-reducing
the culture media using an anaerobic jar containing a GasPak
EZ Anaerobe System sachet for a minimum of 6 h before
inoculation. After inoculation, the GasPak sachet was replaced
for the overnight culture.
Experimental Procedures
The compounds used for the initial growth inhibition screenwere
diluted to a final concentration of 500 µg/ml in Mueller Hinton
broth (BD) and media was inoculated with 5 × 106 colony-
forming units (CFUs) of different C. perfringens strains. Minimal
Inhibitory Concentration values (≥95% growth inhibition,
MIC95) were determined for inhibitory compounds using cation
adjusted Mueller Hinton II broth (BD). Inhibitory compounds
were diluted serially from 512 µg/ml down to 0.5 µg/ml,
inoculated with 5 × 105 CFUs of C. perfringens and then
anaerobically cultured at 37◦C overnight as previously described.
Culture conditions for each compound were performed in
triplicate and bacterial growth was determined by measuring
OD600-values from 1 ml of re-suspended bacteria.
Statistical Analysis
Results are representative of data obtained from repeated
independent experiments. Each value represents the mean ± SD
for three replicates. Statistical analysis was performed using the
two-tailed Student t-test (GraphPad Software, San Diego, CA,
USA).
RESULTS
With renewed interest in gut bacteria and their potential
involvement in the pathogenesis of MS (Bhargava and Mowry,
2014), we wished to determine if oral disease-modifying drugs
(DMDs) have the ability to modulate growth of C. perfringens
since type B and D strains secrete ETX during log-phase
growth. Therefore, we tested if oral DMDs affected the growth
of C. perfringens toxinotypes A–E. We compared the growth
inhibitory effects of Fingolimod, DMF, and Teriflunomide to
that of oral symptom management drugs (SMDs) Baclofen,
Bupropion, and Gabapentin; drugs not thought to alter the
disease course of MS. We exposed C. perfringens cultures to
500µg/ml of each compound, allowed for overnight anaerobic
growth, and determined the optical density (OD600) the following
day. We found that each oral DMD significantly inhibited all
C. perfringens toxinotypes and strains tested, while the oral SMDs
did not (Figure 1A). We then plotted the minimal inhibitory
concentration (MIC) values for each inhibitory compound and
found that Fingolimod was the most potent inhibitor at 4µg/ml
(Figure 1B).
Because Fingolimod is a homolog of D-sphingosine
and Myriocin, both of which have been shown to possess
antimicrobial properties (Fischer et al., 2012), we compared
the inhibitory activity of Fingolimod to these related sphingoid
molecules. We exposed the type strain, C. perfringens ATCC
13124 (type A), to Fingolimod, D-sphingosine, andMyriocin and
identified that, like Fingolimod, D-sphingosine also displayed
inhibitory activity. Myriocin failed to inhibit C. perfringens, but
instead, enhanced bacterial growth (Figure 2A). We then plotted
and compared MICs for Fingolimod and D-sphingosine and
determined that D-sphingosine displayed a similar inhibitory
potency to that of Fingolimod with an MIC95 of 4 µg/ml
(Figure 2B).
Although an antioxidant mechanism has been proposed for
how DMF protects cells against MS mediated damage, DMF was
originally investigated for use as an antimicrobial compound1.
Interestingly, DMF was also found to inhibit the growth of
Clostridium botulinum (Dymicky et al., 1987), a bacterial species
closely related to C. perfringens. DMF is known to be a Michael
acceptor and its ability to affect the redox status of cells
stems from its electrophilic nature. Michael acceptors accept
electrons during the Michael reaction, while nucleophilic thiols
(Michael donors) donate electrons. The Michael reaction results
in covalent alkylation of the sulfhydryl group. This covalent
linkage permanently inactivates thiol-containing molecules if the
thiol is necessary for the molecule’s function, as is the case
for glutathione and its antioxidant properties (Brennan et al.,
2015).
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FIGURE 1 | Oral disease modifying MS drugs inhibit C. perfringens growth, while oral drugs used for MS symptom management do not. (A)
C. perfringens toxinotypes A, B, C, D, E, and two type A clinical isolates (CI1 and CI2) were anaerobically cultured in the presence of 500 µg/ml of oral DMDs,
Fingolimod, DMF, and Teriflunomide, each of which significantly inhibited bacterial growth for all strains tested, similar to what was observed when bacteria were
cultured in the presence of known antibiotic mixture penicillin/streptomycin (pen/strep, 100 U/ml). In contrast, oral SMDs failed to inhibit C. perfringens growth, yielding
OD600-values similar to that of the DMSO vehicle control. Data are presented as means from three independent experiments. Error bars represent standard
deviations, and asterisks indicate that results are statistically significant compared with the DMSO vehicle controls (Student’s t-test, *P < 0.001). (B) Serial dilutions of
inhibitory oral DMDs were performed and the type strain, C. perfringens ATCC 13124 (type A), was cultured in each condition. OD600-values for each concentration
were divided by that of the corresponding dilution for the DMSO vehicle control. MIC-values were plotted for each oral DMD revealing that Fingolimod was the most
potent compound with an MIC95 of 4 µg/ml, compared to 128 µg/ml for DMF and Teriflunomide.
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FIGURE 2 | D-sphingosine, a Fingolimod related compound, inhibits C. perfringens growth. (A) Type strain, C. perfringens ATCC 13124, was anaerobically
cultured in the presence of 500 µg/ml Fingolimod and other sphingoid compounds, D-sphingosine and Myriocin. Like Fingolimod, D-sphingosine also inhibited
C. perfringens growth. However, Myriocin failed to inhibit the bacterium. Instead, Myriocin enhanced C. perfringens growth above that of the DMSO vehicle control.
Data are presented as means from three independent experiments. Error bars represent standard deviations, and asterisks indicate that results are statistically
significant compared with the DMSO vehicle control (gray); Student’s t-test, *P < 0.0001. (B) Serial dilutions of inhibitory sphingoid molecules were performed and C.
perfringens ATCC 13124 was cultured at each dilution. OD600-values for each dilution were divided by that of the corresponding DMSO vehicle control dilution.
MIC-values were plotted for each of the inhibitory sphingoid compounds revealing that D-sphingosine mimics Fingolimod’s antibacterial potency with an MIC95-value
of 4µg/ml.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 January 2017 | Volume 7 | Article 11
Rumah et al. MS Drugs Inhibit Clostridium perfringens
We sought to determine if DMF’s antimicrobial activity
extended to C. perfringens. Furthermore, we examined DMF’s
Michael acceptor activity as pertaining to its antimicrobial
properties. We screened DMF and its metabolites, monomethyl
fumarate (MMF), and fumarate and found that each compound
inhibited the growth of type strain, C. perfringens ATCC
13124. However, their saturated succinate counterparts dimethyl
succinate (DMS), monomethyl succinate (MMS), and succinate,
molecules devoid of Michael acceptor activity due to reduction
of the α, β carbon double bond, failed to inhibit C. perfringens
(Figure 3A). We plotted MIC-values for DMF, MMF, and
fumarate and found that DMF was four times more potent than
either MMF or fumarate (Figure 3B).
Given that Michael acceptor activity was necessary for
C. perfringens inhibition by DMF and its fumarate metabolites,
we sought to determine if unrelated molecules that share the α, β
unsaturated carbonyl structure could also inhibit C. perfringens.
We screened Michael acceptors from a diverse group of chemical
families and found that natural product Michael acceptors
Gambogic acid (a xanthonoid), Parthenolide (a sesquiterpenoid),
and Curcumin (a curcuminoid) each inhibited C. perfringens
(Figure 4A). Interestingly, we found that Gambogic acid was
particularly inhibitory with an MIC95 of 1µg/ml (Figure 4B).
To provide additional evidence that Michael acceptor activity
is indeed critical to the antibacterial properties of α, β unsaturated
carbonyls, we searched the literature to find compounds
for which experimental values of Michael reaction potencies
have been determined. Dinkova-Kostova et al. determined the
potencies of several plant derived Michael acceptors for their
ability to induce cellular quinone reductase activity; a cellular
marker for a compound’s reactivity with sulfhydryl containing
molecules (Dinkova-Kostova et al., 2001). In our study, the
antibacterial potencies of Cinnamic acid, trans-Chalcone, and
Curcumin mirrored the Michael acceptor potencies described
by Dinkova-Kostova and colleagues (Figure 5). Cinnamic acid
was previously shown to be inactive as a Michael acceptor, and
in our hands, this compound failed to inhibit C. perfringens.
Furthermore, Curcumin was found to be approximately four
times more potent than trans-Chalcone (ratio = 4.13; Dinkova-
Kostova et al., 2001). Likewise, we found that Curcumin was
four times more potent than trans-Chalcone as a C. perfringens
inhibitor (ratio= 4).
Since Michael acceptors react with thiols and deplete cellular
glutathione levels (Brennan et al., 2015), we surmised that
Michael acceptor inhibition of C. perfringens might be abolished
by the addition of exogenous glutathione. To test this, we
compared C. perfringens growth in the presence of Michael
acceptors with and without an equal quantity of exogenous
glutathione. We also tested the effect of glutathione on the
inhibitory activity of each of the oral MS DMDs. Glutathione
completely abolished growth inhibition by the known Michael
acceptors in our study, but failed to abolish the inhibitory
effects of Fingolimod and Teriflunomide (Figure 6A). Because
glutathione is an antioxidant, as are vitamins C and E, we sought
to determine if the glutathione’s abrogation of Michael acceptor
antibacterial activity is based on its nucleophilic behavior or due,
more generally, to its antioxidant properties. C. perfringens was
challenged with DMF in the presence of vitamin C, vitamin E, or
the Michael donor, glutathione. Of the antioxidant panel, only
the Michael donor, glutathione, was able to neutralize DMF’s
inhibitory effect (Figure 6B).
DISCUSSION
In this study, we have shown that each of the oral DMDs
approved for the treatment of MS, Fingolimod, Teriflunomide,
and DMF, inhibits the in vitro growth of the epsilon toxin-
secreting gut bacterium, C. perfringens. In contrast, oral therapies
used specifically for symptomatic management fail to prevent
C. perfringens growth. Of note, Fingolimod proved to be
bactericidal, while Teriflunomide and DMF were bacteriostatic
(Supplemental Figure 1). The antibacterial properties of oral
DMDs raises the possibility that modulation of the intestinal
microbiota may play a role in the clinical efficacy of these
compounds. Preventing C. perfringens growth and toxin
production may serve as a specific example of this. Furthermore,
we have identified two distinct classes of molecules capable of
inhibiting C. perfringens; namely sphingoid compounds such as
Fingolimod and D-sphingosine, and Michael acceptors such as
DMF, its fumarate metabolites, and various natural products that
are α, β unsaturated carbonyls.
Important factors must be considered when attempting to
extrapolate these in vitro findings to what may be occurring in the
human gut. First, how do the in vitro inhibitory concentrations
compare to concentrations found in the human gut? The resting
volume of the human stomach is∼0.08 L (Johnson, 1994), which
yields a calculated gut concentration of 6.3µg/ml for Fingolimod
(MIC95 = 4µg/ml), 87–175µg/ml for Teriflunomide (MIC95
= 128µg/ml), and 1500–3000 µg/ml for DMF (MIC95 =
128µg/ml). Therefore, each compound’s MIC95 is within the
calculated range of the therapeutic concentration that will enter
the small intestine. Furthermore, DMF is a delayed released
capsule that dissolves in the more basic pH of the small intestine
(Gold et al., 2016). Local release of DMF may increase its
concentration in the small intestine where C. perfringens resides.
Second, our experimental growth conditions are likely to
be more favorable to C. perfringens growth than the intestinal
milieu. Anexic, in vitro growth protects C. perfringens from
competition with other bacteria for nutrients. In addition,
C. perfringens will not be exposed to toxic molecules secreted
by competing bacteria such as bacteriocins or host derived
antibacterial molecules such as defensins. Therefore, the MIC95
for each of the oral DMDs may be considerably less in an
environment such as the human intestine where C. perfringens
must contend with a multitude of external factors.
Conversely, each of the oral DMDs possesses a significant
degree of hydrophobicity, and lipid-binding molecules within
the gut lumen may sequester these compounds, preventing toxic
interactions with gut bacteria. Specifically considering DMF, a
Michael acceptor, extracellular nucleophiles present in the gut
may react with its electrophilic β carbon before it can enter the
bacterial cell, possibly diminishing its antibacterial activity within
the gut.
DMF’s Michael reaction-dependent inhibition of
C. perfringens growth may be explained by its ability to
deplete this bacterium of thiol containing compounds. It is
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FIGURE 3 | Fumarates inhibit C. perfringens growth while their related saturated succinates do not. (A) The anaerobic growth of C. perfringens ATCC
13124 was compared for DMF and its corresponding succinate (DMS), MMF and its corresponding succinate MMS, fumarate, and succinate. In each case, the
unsaturated fumarate compounds (red) displayed inhibitory activity, while the saturated succinates (blue) did not. Data are presented as means from three
independent experiments. Error bars represent standard deviations, and asterisks indicate that the inhibition of bacterial growth observed in the presence of
unsaturated fumarates is statistically significant when compared to the bacterial growth observed in the presence of corresponding saturated succinates; Student’s
t-test, *P < 0.0001). (B) Serial dilutions of inhibitory fumarate compounds were performed and C. perfringens ATCC 13124 was cultured at each dilution.
OD600-values for each dilution were divided by that of the corresponding DMSO vehicle control dilution. MIC-values were plotted for each of the inhibitory fumarates
revealing that DMF is approximately four times more potent that MMF and fumarate.
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FIGURE 4 | Natural product Michael acceptors inhibit C. perfringens growth. (A) Plant derived Michael acceptors were tested for inhibitory activity against
C. perfringens ATCC 13124. Bacteria were grown anaerobically in the presence of 500 µg/ml Gambogic acid, Parthenolide, and Curcumin. Each natural product
Michael acceptor successfully inhibited C. perfringens growth, similar to what was observed when bacteria were cultured in the presence of known antibiotic
penicillin/streptomycin (pen/strep, 100 U/ml). Data are presented as means from three independent experiments. Error bars represent standard deviations, and
asterisks indicate that results are statistically significant compared with the DMSO vehicle control (gray); Student’s t-test, *P < 0.0001. (B) Serial dilutions of inhibitory
natural product Michael acceptors were performed and C. perfringens ATCC 13124 was cultured at each dilution. OD600-values for each dilution were divided by that
of the corresponding DMSO vehicle control dilution. MIC-values were plotted for each compound revealing Gambogic acid as the most potent with an MIC95 of 1
µg/ml when compared to Parthenolide and Curcumin, which each inhibit C. perfringens at 64 µg/ml.
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FIGURE 5 | Michael acceptor C. perfringens growth inhibition reflects known reactivity potencies. Serial dilutions of α, β unsaturated carbonyls were
performed and C. perfringens ATCC 13124 was cultured at each dilution. OD600-values for each dilution were divided by that of the corresponding DMSO vehicle
control dilution. MIC-values were plotted for each compound revealing that Cinnamic acid displays no inhibitory activity, while Curcumin is four times more potent than
trans-Chalcone. The relative inhibitory potencies of each compound corresponds almost exactly with the relative Michael acceptor potencies as demonstrated by
Dinkova-Kostova et al. (2001).
striking that nucleophilic thiols not only play an important role
in mammalian cell homeostasis, but are also necessary substrates
for C. perfringens growth. This bacterium depends on an organic
source of sulfur (thiols) and will not grow with strictly inorganic
sources (SO2−4 , SO
2−
3 , S2O3
2−, and Si; Fuchs and Bonde, 1957).
Therefore, depleting C. perfringens of thiols may contribute to
Michael acceptor mediated growth inhibition.
Although Teriflunomide is an α, β unsaturated carbonyl,
we have shown that glutathione has no effect on its ability
to inhibit C. perfringens growth. It is tempting to speculate
that Teriflunomide inhibits de novo pyrimidine synthesis
in rapidly dividing bacterial cells, as it does in mammalian
cells, via inhibition of dihydroorotate dehydrogenase; a
gene that has been annotated for C. perfringens in the
Uniprot Knowledgebase. However, we have not examined
the inhibitory mechanism of Teriflunomide in the present
study.
That Michael acceptors such as DMF and its fumarate
metabolites inhibit C. perfringens may open the door to
development of new oral MS therapies derived from the Michael
acceptor functional class. Gambogic acid has been used in Eastern
medicine for centuries to treat intestinal ailments and parasites
(Wu et al., 2004), and in our hands, it displays an impressive
antibacterial potency (MIC95 = 1µg/ml).
We searched for Michael acceptors currently approved
for human use that possess no known immunosuppressive
properties. The naphthoquinone, Menadione (vitamin K3),
is a synthetic precursor for vitamin K. It is commonly
used as a dietary supplement for livestock and as a cost
effective vitamin K replacement therapy in developing countries.
Of note, Menadione has recently been shown to inhibit
S. aureus and B. anthracis growth, and to suppress S. aureus
secretion of toxic shock syndrome toxin 1 (TSST-1; Schlievert
et al., 2013). Similarly, we find that Menadione inhibits C.
perfringens growth, but related compounds with long aliphatic
side chains, vitamin K1, vitamin K2, and ubiquinone do not
(Supplemental Figure 2A).WhileMenadione’sMIC95-value was
found to be 64µg/ml (Supplemental Figure 2B), the inactivity
of the Menadione related compounds, all of which are electron
carriers in the electron transport chain, might be due to
the fact that they are sequestered in the cell membrane
by their aliphatic side chains. Membrane sequestration may
protect cytosolic nucleophiles from undergoingMichael addition
and subsequent depletion. Additionally, unlike Menadione but
similar to Teriflunomide, these molecules possess a third σ bond
at the β carbon position. This may prevent nucleophilic attack
due to steric hindrance and abolish Michael acceptor activity
(Schwöbel et al., 2010).
In light of the serious side effects associated with current
oral DMDs, this study may be of immediate clinical importance.
Some of these adverse effects are due to immunosuppression of
the CNS, as evidenced by increased risk of JC virus infection
and progressive multifocal leukoencephalopathy (PML, FDA
Drug Safety Communication, 2014; Brooks, 2015). Perhaps new
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FIGURE 6 | The Michael donor, glutathione (GSH), abolishes Michael acceptor inhibition of C. perfringens growth. (A) C. perfringens ATCC 13124 was
cultured anaerobically at a Michael acceptor (DMF, Parthenolide, and trans-Chalcone), and non-Michael acceptor (Fingolimod and Teriflunomide) concentration of
500µg/ml, with (red) or without (blue) the addition of an equal quantity of exogenous Michael donor, GSH. Only Michael acceptor mediated growth inhibition could be
abolished by the addition of exogenous GSH. The inhibitory activity Fingolimod and Teriflunomide remained unaffected by the presence of GSH, similar to what was
observed when bacteria were cultured in the presence of pen/strep and GSH. Data are presented as means from three independent experiments. Error bars represent
standard deviations, and asterisks indicate that GSH aided growth recovery is statistically significant when compared to the lack of growth recovery in the absence of
GSH; Student’s t-test, *P < 0.001. (B) C. perfringens ATCC 13124 was cultured in the presence of DMF, vitamin C, vitamin E, and GSH each at concentration of
250µg/ml. Only the Michael acceptor, DMF, inhibited bacterial growth. DMF was then paired with the antioxidants, vitamin C, vitamin E, and GSH at concentrations of
250µg/ml for each compound. The Michael donor antioxidant, GSH, abolished DMF inhibition. However, the non-Michael donor antioxidants, vitamin C and vitamin
E, were unable to abolish DMF’s inhibitory effect on C. perfringens growth. Data are presented as means from three independent experiments. Error bars represent
standard deviations, and asterisks indicate that results are statistically significant compared with the DMF control (gray); Student’s t-test, *P < 0.001.
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TABLE 2 | Minimal Inhibitor Concentrations for all inhibitory compounds
used in the study.
Compound MIC95 (µg/ml)
Gambogic Acid 1
Fingolimod 4
D-sphingosine 4
Curcumin 64
Parthenolide 64
Menadione (vitamin K3) 64
Teriflunomide 128
Dimethyl fumarate (DMF) 128
Trans-Chalcone 256
Monomethyl fumarate (MMF) 512
Fumarate 512
antibacterial compounds based on these early oral DMDs, but
lacking their immunosuppressive properties, may be of use in
treating MS. For example, Fingolimod/D-sphingosine related
compounds lacking hydroxyl head groups will not undergo
phosphorylation and will not target lymphocyte S1PR1. Such
compounds would not be immunosuppressive and may reduce
the risk of JC virus infection and the development of PML.
Along these lines, we have tabulated the MIC95-values for each
inhibitory compound used in this study (Table 2).
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Supplemental Figure 1 | Fingolimod is bactericidal, while DMF and
Teriflunomide are bacteriostatic. C. perfringens ATCC 13124 was
anaerobically cultured to stationary phase and exposed to Fingolimod (500 µg/ml),
DMF (500 µg/ml), Teriflunomide (500 µg/ml), pen/strep (100U/ml) or DMSO vehicle
control for 4 h under anaerobic conditions. Treated cultures were diluted 1000 fold
in fresh, pre-reduced Mueller Hinton broth and cultured anaerobically. Fingolimod
inhibited C. perfringens growth in a bactericidal fashion, similar to what was
observed with the known bactericidal antibiotic mixture pen/strep, as
post-treatment dilution and repeat culture failed to restore bacterial growth.
Conversely, DMF and Teriflunomide were shown to be bacteriostatic, as
post-treatment dilution and culture successfully restored bacterial growth. Data
are presented as means from three independent experiments. Error bars represent
standard deviations, and asterisks indicate that results are statistically significant
compared with the DMSO vehicle control (gray); Student’s t-test, ∗P < 0.0001.
Supplemental Figure 2 | Synthetic vitamin K3, Menadione, inhibits
C. perfringens growth. (A) C. perfringens ATCC 13124 was anaerobically
cultured in the presence of vitamin K homologs, vitamins K1, K2, K3, and
ubiquinone. Only the synthetic vitamin K3 (Menadione) inhibited bacterial growth,
similar to what was observed when bacteria were cultured in the presence known
antibiotic penicillin/streptomycin (pen/strep, 100 U/ml). Conversely, bacteria
derived vitamin K2 enhanced C. perfringens growth, while plant derived vitamin
K1 and mammalian ubiquinone yielded OD600-values similar to that of the DMSO
vehicle control. Data are presented as means from three independent
experiments. Error bars represent standard deviations, and asterisks indicate that
results are statistically significant compared with the DMSO vehicle control (gray);
Student’s t-test, ∗P < 0.001. (B) Serial dilutions of Menadione were performed
and C. perfringens ATCC 13124 was cultured at each dilution. OD600-values for
each dilution were divided by that of the corresponding DMSO vehicle control
dilution. MIC-values were plotted yielding an MIC95-value of 64µg/ml.
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